These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26544922)

  • 1. Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
    Guida A; Masini C; Milella M; Di Lorenzo G; Santoni M; Prati V; Porta C; Cosmai L; Donati D; del Giovane C; Mighali P; Sabbatini R
    Future Oncol; 2015; 11(23):3159-66. PubMed ID: 26544922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
    Yang L; Alyasova A; Ye D; Ridolfi A; Dezzani L; Motzer RJ
    BMC Cancer; 2018 Feb; 18(1):195. PubMed ID: 29454306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.
    Czarnecka AM; Kawecki M; Lian F; Korniluk J; Szczylik C
    Future Oncol; 2015; 11(16):2267-82. PubMed ID: 26260806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
    Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
    Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.
    Rizzo M; Facchini G; Savastano C; Di Lorenzo G; Lucia LD; Maiorino L; Casale B; Grimaldi G; Formato R; Febbraro A; Cartenì G
    Future Oncol; 2015; 11(2):219-24. PubMed ID: 25078333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
    Glen H
    Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.
    Bergmann L; Kube U; Doehn C; Steiner T; Goebell PJ; Kindler M; Herrmann E; Janssen J; Weikert S; Scheffler MT; Schmitz J; Albrecht M; Staehler M
    BMC Cancer; 2015 Apr; 15():303. PubMed ID: 25925846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
    Tsimafeyeu I; Snegovoy A; Varlamov S; Safina S; Varlamov I; Gurina L; Manzuk L
    Target Oncol; 2015 Sep; 10(3):423-7. PubMed ID: 25466382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results.
    Maráz A; Csejtei A; Kocsis J; Szűcs M; Kahán Z; Bodoky G; Dank M; Mangel L; Révész J; Varga Z; Géczi L
    Pathol Oncol Res; 2019 Jan; 25(1):149-156. PubMed ID: 29027615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.
    Huang WK; Liaw CC; Pang ST; Chuang CK; Chiang YJ; Wu CT; Chang YH; Wang HM; Lin YC; Hsieh JJ; Ou LY; Tsai SI; Yang CH; Yang CT; Chang JW
    Chang Gung Med J; 2012; 35(5):402-7. PubMed ID: 23127345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
    Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
    Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
    Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
    Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
    Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan.
    Akaza H; Kurihara R; Katsura A; Harumiya M; Ushida N
    Jpn J Clin Oncol; 2019 Oct; 49(10):956-964. PubMed ID: 31135920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.